Physician profile
Loritz M Chavez
NPI 1801816517
$1,199.75
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $134 · 2021: $52.23 · 2022: $191 · 2023: $503 · 2024: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $174.19 | 2022-2024 | Xarelto |
| Amarin Pharma, INC. | $147.17 | 2020-2021 | |
| Vifor Pharma, INC. | $110.77 | 2022-2023 | Veltassa |
| Pfizer INC. | $108.38 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.15 | 2023-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $102.17 | 2022-2024 | |
| Abbvie INC. | $93.50 | 2022-2024 | Dalvance |
| Gilead Sciences, INC. | $67.95 | 2022-2024 | Veklury |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.34 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $59.55 | 2023 | Verquvo, Dificid, Zerbaxa |
| Ucb, INC. | $50.16 | 2022-2023 | Briviact |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.86 | 2023-2024 | Lifevest |
| Ferring Pharmaceuticals INC. | $32.68 | 2023 | Rebyota |
| Inari Medical, INC. | $28.21 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $19.67 | 2023 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loritz Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.